Back to search

Article

CDK8 remodels the tumor microenvironment to resist the therapeutic efficacy of targeted KRAS <sup>G12D</sup> inhibition in pancreatic ductal adenocarcinoma

2025-02-02

Abstract excerpt

Mutations in KRAS are a dominant driver of pancreatic ductal adenocarcinoma (PDAC), with over 40% of PDAC patients presenting with KRAS G12D mutations. The recent development of small molecule inhibitors targeting KRAS G12D has enabled targeting of mutant KRAS signaling and suppression of PDAC; however, the contribution of the tumor microenvironment (TME) to the sustained therapeutic efficacy of KRAS G12D inh...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
fe095a23-886c-57b8-af1e-42d4ccc84fbf
DOI
10.1101/2025.01.29.635543
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
CDK8 remodels the tumor microenvironment to resist the therapeutic efficacy of targeted KRAS <sup>G12D</sup> inhibition in pancreatic ductal adenocarcinomaDOI 10.1101/2025.01.29.635543
CDK8 remodels the tumor microenvironment and promotes resistance to KRASG12D inhibitors and daraxonrasib in PDAC.Semantic proximity
The Extracellular Niche and Tumor Microenvironment Enhance KRAS Inhibitor Efficacy in Pancreatic Cancer.Semantic proximity
Pharmacologically targeting KRAS <sup>G12D</sup> in PDAC models: tumor cell intrinsic and extrinsic impactSemantic proximity
Current advances in immunotherapy for KRAS-Mutant pancreatic cancer.Semantic proximity
Single-cell and spatially resolved atlas of pancreatic cancer reveals immunophenotypes associated with clinical outcomeSemantic proximity
High-Dimensional Protein Analysis Uncovers Distinct Immunological and Stromal Signatures Between Primary and Metastatic Pancreatic Ductal AdenocarcinomaSemantic proximity
Recent Anti-KRASG12D Therapies: A “Possible Impossibility” for Pancreatic Ductal AdenocarcinomaSemantic proximity
Distinct Mechanisms of Innate and Adaptive Immune Regulation Underlie Poor Oncologic Outcomes Associated with <i>KRAS-TP53</i> Co-Alteration in Pancreatic CancerSemantic proximity
Integrating multi-modal transcriptomics identifies cellular subtypes with distinct roles in PDAC progressionSemantic proximity
Distinct clinical outcomes and biological features of specific KRAS mutants in human pancreatic cancer.Semantic proximity
Single cell RNA-seq reveals the CCL5/SDC1 receptor-ligand interaction between T cells and tumor cells in pancreatic cancerSemantic proximity
Integrating multi-modal transcriptomics identifies cellular subtypes with distinct roles in PDAC progressionSemantic proximity
Select a neighboring publication to make it the new centre.